Comparison of glucose-lowering effect between long-acting insulin analogues in patients with type 2 diabetes mellitus

Comparison of glucose-lowering effect between long-acting insulin analogues in patients with type 2 diabetes mellitus - Long-acting insulin in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013414

Enrollment

Registered

2014-03-17

Start date

2014-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

insulin glargine insulin degludec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients treated with intensive insulin therapy

Exclusion criteria

Exclusion criteria: - severe hepatic, renal, and/or cardiac disease - hypersensitivity to insulin glargine and/or insulin degludec - pregnanct, or breast feeding females

Design outcomes

Primary

Measure	Time frame
Daily blood glucose profiles	—

Countries

Japan

Contacts

Public ContactToshihiko Shiraiwa

Shiraiwa Medical Clinic Shiraiwa Medical Clinic

shiwaira@endmet.med.osaka-u.ac.jp072-971-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026